• LAST PRICE
    9.6135
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    9.4000/ 1
  • Ask / Lots
    12.9000/ 3
  • Open / Previous Close
    0.0000 / 9.6135
  • Day Range
    ---
  • 52 Week Range
    Low 7.1100
    High 13.1280
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 9.551
TimeVolumeDXR
10:15 ET1009.4937
11:22 ET1089.57
11:24 ET3029.57
11:26 ET2349.6135
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesDXR
Daxor Corp
46.1M
-265.8x
---
United StatesWINV
WinVest Acquisition Corp
45.1M
-53.3x
---
United StatesAOGO
Arogo Capital Acquisition Corp
47.3M
20.5x
---
United StatesBNIX
Bannix Acquisition Corp
44.7M
-649.3x
---
United StatesACAC
Acri Capital Acquisition Corp
44.5M
81.9x
---
United StatesINTE
Integral Acquisition Corp 1
44.2M
35.2x
---
As of 2024-04-18

Company Information

Daxor Corporation is a blood volume measurement technology company, which is focused on blood volume testing innovation. The Company has developed and marketed the Blood Volume Analyzer (BVA-100), the diagnostic blood test cleared by the food and drug administration (FDA) to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. It is also focused on advancing healthcare by enabling optimal fluid management with blood volume analysis. It has several ongoing trials in the areas of heart failure treatment with support from the National Institutes of Health (NIH) and is under contract developing analyzers.

Contact Information

Headquarters
SUITE 7120, 350 FIFTH AVENUENEW YORK, NY, United States 10118
Phone
212-244-0555
Fax
212-244-0806

Executives

Chairman of the Board, President, Chief Executive Officer
Michael Feldschuh
Chief Financial Officer, Chief Compliance Officer
Robert Michel
Chief Scientific Officer, Director
Jonathan Feldschuh
Independent Director
Henry Cremisi
Independent Director
Caleb Desrosiers

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$46.1M
Revenue (TTM)
$163.4K
Shares Outstanding
4.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.45
EPS
$-0.04
Book Value
$7.08
P/E Ratio
-265.8x
Price/Sales (TTM)
281.9
Price/Cash Flow (TTM)
---
Operating Margin
-541.89%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.